Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1361-1370 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|February 28, 2019
Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activityDaniel F Lusche, Michael R Klemme, Benjamin A Soll, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Mabs|February 23, 2019
Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®Yanpeng Xu, Liqi Xie, Erhui Zhang, et al.
Mabs|January 25, 2021
Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab librariesPallavi Bhatta, Kevin D Whale, Amy K Sawtell, et al.
Mabs|March 14, 2017
Generation and characterization of protective antibodies to Marburg virusJeffrey W Froude, Thibaut Pelat, Sebastian Miethe, et al.
Mabs|March 9, 2017
Glycation of antibodies: Modification, methods and potential effects on biological functionsBingchuan Wei, Kelsey Berning, Cynthia Quan, et al.
Mabs|March 9, 2017
TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targetsDevin B Lowe, Camille K Bivens, Alexis S Mobley, et al.
Mabs|March 11, 2017
Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approachesYang Yang, Guanbo Wang, Ting Song, et al.
Mabs|April 12, 2025
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAbMegan H Cleveland, Ioannis L Karageorgos, John P Marino, et al.
Mabs|April 9, 2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugateHwai Wen Chang, Gerhard Frey, Jing Wang, et al.
Pageof 178

Showing results (1361-1370 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|February 28, 2019
Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activityDaniel F Lusche, Michael R Klemme, Benjamin A Soll, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Mabs|February 23, 2019
Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®Yanpeng Xu, Liqi Xie, Erhui Zhang, et al.
Mabs|January 25, 2021
Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab librariesPallavi Bhatta, Kevin D Whale, Amy K Sawtell, et al.
Mabs|March 14, 2017
Generation and characterization of protective antibodies to Marburg virusJeffrey W Froude, Thibaut Pelat, Sebastian Miethe, et al.
Mabs|March 9, 2017
Glycation of antibodies: Modification, methods and potential effects on biological functionsBingchuan Wei, Kelsey Berning, Cynthia Quan, et al.
Mabs|March 9, 2017
TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targetsDevin B Lowe, Camille K Bivens, Alexis S Mobley, et al.
Mabs|March 11, 2017
Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approachesYang Yang, Guanbo Wang, Ting Song, et al.
Mabs|April 12, 2025
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAbMegan H Cleveland, Ioannis L Karageorgos, John P Marino, et al.
Mabs|April 9, 2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugateHwai Wen Chang, Gerhard Frey, Jing Wang, et al.
Pageof 178